Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

RGNX stock hub

REGENXBIO Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

RGNXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

544.6M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

RGNX

In the news

Latest news · RGNX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-107

P25 -105.6P50 -46.5P75 -3.1

ROIC-111.7

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All RGNX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

209

Groups with data

Currency

USD

Showing 209 of 209 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001590877
Company name	REGENXBIO Inc.
Country	United States
Country code	US
Cusip	75901B107
Employees	371
Employees Change	18%
Employees Change Percent	5.1
Enterprise value	$564.2M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2015-09-17
Isin	US75901B1070
Last refreshed	2026-05-10
Market cap	$544.6M
Market cap category	Small-Cap
Price	$10.55
Price currency	USD
Rev Per Employee	459,409.7x
Sector	Healthcare
Sic	2836
Symbol	RGNX
Website	https://www.regenxbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-35.6%
EV Sales Forward	2.24x
EV/Sales	3.31x
FCF yield	-23.21%
P/B ratio	5.23x
P/S ratio	3.2x
PS Forward	2.16x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-94.58%
EBITDA Margin	-85.42%
Gross margin	-45.86%
Gross Profit	$-78.2M
Net Income	$-193.9M
Net Income Growth Years	3%
Pretax Margin	-113.75%
Profit Margin	-113.75%
Profit Per Employee	$-522,582
ROA	-21.93
Roa5y	-15.73
ROCE	-48.13
ROE	-107
Roe5y	-54.31
ROIC	-111.7
Roic5y	-65.82

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	0.51%
Cagr1y	45.76%
Cagr3y	-17.63%
Cagr5y	-21.89%
EPS Growth Years	3
Revenue Growth	104.54x
Revenue Growth Q	43.01x
Revenue Growth Quarters	2x
Revenue Growth Years	1x
Revenue Growth3 Y	14.78x
Revenue Growth5 Y	1.97x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.37
Assets	$453M
Cash	$230.1M
Current Assets	$281.3M
Current Liabilities	$118.1M
Debt	$260.5M
Debt Equity	$2.54
Equity	$102.7M
Interest Coverage	-3.58
Liabilities	$350.3M
Long Term Assets	$171.8M
Long Term Liabilities	$232.2M
Net Cash	$-19.7M
Net Cash By Market Cap	$-3.61
Net Debt Equity	$0.19
Tangible Book Value	$102.7M
Tangible Book Value Per Share	$2.02
WACC	11.46

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.38
Net Working Capital	$-19M
Quick ratio	2.27
Working Capital	$163.2M
Working Capital Turnover	$1.01

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-4.17%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	5.18%
1Y total return	45.72%
200-day SMA	10.57
3Y total return	-44.12%
50-day SMA	8.93
50-day SMA vs 200-day SMA	50under200
5Y total return	-70.91%
All Time High	85.1
All Time High Change	-87.6%
All Time High Date	2018-07-10
All Time Low	5.04
All Time Low Change	109.53%
All Time Low Date	2025-04-09
ATR	0.6
Beta	1.12
Beta1y	2.06
Beta2y	2.25
Ch YTD	-26.74
High	10.86
High52	16.19
High52 Date	2026-01-22
High52ch	-34.84%
Low	10.2
Low52	6.89
Low52 Date	2025-05-08
Low52ch	53.12%
Ma50ch	18.11%
Premarket Change Percent	2.21
Premarket Price	$10.65
Premarket Volume	21,617
Price vs 200-day SMA	-0.15%
RSI	67.33
RSI Monthly	46.97
RSI Weekly	52.37
Sharpe ratio	0.82x
Sortino ratio	1.34
Total Return	-4.17%
Tr YTD	-26.74
Tr1m	19.89%
Tr1w	15.68%
Tr3m	2.13%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	8
Analyst Count Top	2
Analyst Price Target Top	$47.5
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-1.4
Earnings Revenue Estimate	24,955,392x
Earnings Revenue Estimate Growth	-71.96x
Operating Income	$-161.2M
Operating margin	-94.58
Price target	$28.75
Price Target Change	$173
Price Target Change Top	$350

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	43,001,937%
Float Percent	83.31%
Shares Insiders	8.23%
Shares Institutions	71.67%
Shares Out	51,617,233
Shares Qo Q	0.12%
Shares Yo Y	4.17%
Short Float	16.15%
Short Ratio	9.75
Short Shares	13.45

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-160.9M
Average Volume	708,252.75x
Bv Per Share	2.02
CAPEX	$-2.4M
Ch10y	5.18
Ch1m	19.89
Ch1w	15.68
Ch1y	45.72
Ch3m	2.13
Ch3y	-44.12
Ch5y	-70.91
Ch6m	-5.89
Change	1.25%
Change From Open	-0.75
Close	10.42
Days Gap	2.02
Depreciation Amortization	15,615,000
Dollar Volume	14,552,712.2
Earnings Date	2026-05-14
Earnings Time	bmo
EBIT	$-161.2M
EBITDA	$-145.6M
EPS	$-3.76
F Score	3
FCF	$-126.4M
FCF EV Yield	-22.4x
FCF Per Share	$-2.45
Financing CF	116,771,000
Fiscal Year End	December
Founded	2,008
Investing CF	-15,868,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-05
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-03-05
Ma150	11.1
Ma150ch	-4.95%
Ma20	9.28
Ma20ch	13.65%
Net CF	-23,060,000
Next Earnings Date	2026-05-14
Open	10.63
Optionable	Yes
Position In Range	53.03
Post Close	10.55
Postmarket Change Percent	1.23
Postmarket Price	$10.68
Ppne	152,011,000
Pre Close	10.42
Price Date	2026-05-08
Ptbv Ratio	5.3
Relative Volume	1.95x
Revenue	170,441,000x
SBC By Revenue	20.28x
Share Based Comp	34,563,000
Tr6m	-5.89%
Us State	Maryland
Volume	1,379,404
Z Score	-3.04

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does RGNX pay a dividend?

Capital-return profile for this ticker.

Performance

RGNX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns RGNX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+71.7%

Float: +83.3% of shares outstanding

Insider ownership

+8.2%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

RGNX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

67.3

Neutral momentum band

Price vs 200-day MA

-0.2%

50/200-day relationship not available

Beta (5Y)

1.12

Moves roughly with the market

Sharpe ratio

0.82

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About RGNX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current RGNX stock rating?

REGENXBIO Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full RGNX analysis?

The full report lives at /stocks/RGNX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for RGNX?

The latest report frames RGNX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the RGNX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.